Skip to main content
null
JHEOR
  • Menu
  • Articles
    • Author Correction
    • Autoimmune Diseases
    • Brief Report
    • Cardiovascular Conditions
    • Commentary
    • Correspondence
    • Dermatological Diseases
    • Endocrine Diseases
    • Gastrointestinal Conditions
    • General Indications
    • Genetic Disorders
    • Hematology
    • Infectious Diseases
    • Methodology and Healthcare Policy
    • Nephrologic/Hepatologic Conditions
    • Neurological Disorders
    • Oncology
    • Ophthalmology
    • Other Conditions
    • Perspective
    • Psychological Conditions
    • Respiratory Diseases
    • Trauma Induced Conditions
    • Urological/Gynecological Diseases
    • All
  • For Authors
  • Editorial Board
  • About
  • Issues
  • Blog
  • Journal Policies
  • For Reviewers
  • search

RSS Feed

Enter the URL below into your favorite RSS reader.

http://localhost:42874/feed
Dermatological Diseases
Vol. 2, Issue 1, 2014October 01, 2014 EDT

Willingness-to-pay to access Ingenol Mebutate Gel for Actinic Keratosis Treatment in the U.S. Setting

Michael Willis, Sandra Erntoft, Sofie Persson, Jenny M. Norlin, Ulf Persson,
topical agentscontingent valuationpatient preferenceslocal skin reactionsactinic keratosiswillingness-to-pay
Copyright Logoccby-4.0 • https://doi.org/10.36469/9879
JHEOR
1.
Willis M, Erntoft S, Persson S, Norlin JM, Persson U. Willingness-to-pay to access Ingenol Mebutate Gel for Actinic Keratosis Treatment in the U.S. Setting. JHEOR. 2014;2(1):1-14. doi:10.36469/​9879
Save article as...▾

View more stats

This website uses cookies

We use cookies to enhance your experience and support COUNTER Metrics for transparent reporting of readership statistics. Cookie data is not sold to third parties or used for marketing purposes.

Powered by Scholastica, the modern academic journal management system